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HIV-1 reverse transcription represents the predomi-
nant target for pharmacological inhibition of viral
replication, but cell-intrinsic mechanisms that can
block HIV-1 reverse transcription in a clinically signif-
icant way are poorly defined. We find that effective
HIV-1 reverse transcription depends on the phos-
phorylation of viral reverse transcriptase by host cy-
clin-dependent kinase (CDK) 2 at a highly conserved
Threonine residue. CDK2-dependent phosphoryla-
tion increased the efficacy and stability of viral
reverse transcriptase and enhanced viral fitness.
Interestingly, p21, a cell-intrinsic CDK inhibitor that
is upregulated inCD4+ T cells from ‘‘elite controllers,’’
potently inhibited CDK2-dependent phosphoryla-
tion of HIV-1 reverse transcriptase and significantly
reduced the efficacy of viral reverse transcription.
These data suggest that p21 can indirectly block
HIV-1 reverse transcription by inhibiting host cofac-
tors supporting HIV-1 replication and identify sites
of viral vulnerability that are effectively targeted in
persons with natural control of HIV-1 replication.
INTRODUCTION
CD4+ T lymphocytes represent themajor target cells for infection
with HIV-1, but the susceptibility of these cells to HIV-1 varies
considerably among different persons (Ciuffi et al., 2004). This
variation appears to be primarily related to the relative presence
or absence of specific host proteins that can modulate the effi-
cacy of HIV-1 replication by inhibiting specific steps of the viral
lifecycle. Over the recent years, several of such host molecules
have been identified (Harris et al., 2012; Malim and Bieniasz,
2012), but the influence of these host factors on clinical rates
of HIV-1 disease progression and on the ability to maintain anti-
retroviral drug-free control of HIV-1 replication in elite controllers
remains uncertain. Interestingly, a significantly reduced suscep-
tibility of host CD4+ T cells to HIV-1 has previously been demon-Cell Hstrated in two geographically distinct cohorts of elite controllers
who naturally maintain undetectable levels of HIV-1 replication in
the absence of antiretroviral therapy (Chen et al., 2011; Sa´ez-
Cirio´n et al., 2011). This raises the possibility that specific
host proteins can reduce viral replication steps in these patients
and contribute to a CD4+ T cell-intrinsic mechanism of HIV-1
immune defense. Yet, classical HIV-1 restriction factors with
known direct inhibitory effects on HIV-1 replication, such as
APOBEC3G, TRIM5a, and BST2, have reduced expression
levels in CD4+ T cells from elite controllers in comparison to
progressors (Abdel-Mohsen et al., 2013; Rotger et al., 2009;
Vigneault et al., 2011); therefore, these molecules are unlikely
to contribute to HIV-1 immune defense or cell-intrinsic restriction
of HIV-1 replication in a clinically significant way.
Instead of blockingHIV-1 replication steps through direct inter-
actionswith the virus, specific host proteinsmay indirectly restrict
HIV-1 replication by inhibiting host factors that are required for
HIV-1 to replicate effectively. A large number of such HIV-1 ‘‘de-
pendency factors’’ have been identified (Brass et al., 2008; Ko¨nig
et al., 2008; Zhou et al., 2008), and the requirement of these mol-
ecules for effectiveHIV-1 replicationmay represent a specific viral
vulnerability. p21 (waf-1/cip-1) is a host protein from the cyclin-
dependent kinase inhibitor (CDKI) family that is uniquely upregu-
lated in CD4+ T cells frommany elite controllers in comparison to
both HIV-1-negative persons and individuals with progressive
infection (Chen et al., 2011; Sa´ez-Cirio´n et al., 2011) and has
been implicated with restriction of HIV-1 replication in CD4+
T cells (Chen et al., 2011; Elahi et al., 2012), hematopoietic stem
cells (Zhang et al., 2007), and macrophages (Allouch et al.,
2013; Bergamaschi et al., 2009), although the underlying mecha-
nisms for inhibiting HIV-1 seem to vary in each of these cell pop-
ulations. One proposed hypothesis is that p21 can inhibit HIV-1
replication by blocking cyclin-dependent kinases (CDK), a group
of host molecules with an emerging function as host cofactors
supporting different HIV-1 replication steps. Indeed, CDK9 (Man-
ceboet al., 1997) andCDK2 (Breuer et al., 2012;Denget al., 2002)
have recognized roles for increasing transcriptional elongation of
HIV-1 mRNA through phosphorylation of polymerase II, and this
process can be intercepted by cell-intrinsic inhibitors of CDKs,
such as p21 (Chen et al., 2011).
In the present study, we show that CDK2 can support HIV-1
reverse transcription through direct phosphorylation of HIV-1ost & Microbe 15, 717–728, June 11, 2014 ª2014 Elsevier Inc. 717
Figure 1. Host CDK2 Supports HIV-1 Reverse Transcription
Activated CD4+ T cells were infected ex vivo with GFP-encoding, R5-tropic HIV-1, or GFP-encoding VSV-G-pseudotyped HIV-1 in the presence or absence of the
pharmaceutical CDK inhibitors Roscovitine and Olomoucine or after transfection with siRNA directed against CDK2 or CDK7.
(A, D, G, and J) Representative flow cytometry plots showing infected GFP+ CD4+ cells.
(B, E, H, and K) Proportions of GFP+ CD4+ T cells after exposure to indicated CDK inhibitors or CDK-directed siRNAs.
(C, F, I, and L) Quantitative analysis of early, intermediate, and late HIV-1 RT transcripts in CD4+ T cells from the indicated study groups.
All statistical comparisons were performed with Student’s t tests. *p<0.05; **p<0.01; ***p<0.001. Data are expressed as box and whisker plots indicating the
median, 25% and 75% percentile, and minimum and maximum of all data. See also Figure S1.
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Cell-Intrinsic Inhibition of HIV-1 RTreverse transcriptase (RT) at a highly conserved amino acid
residue, that this phosphorylation is functionally relevant
for maintaining RT activity, stability, and viral fitness, and
that CDK2-dependent RT phosphorylation can be effectively
blocked by p21. Thus, these data suggest an indirect mecha-
nism for inhibition of HIV-1 reverse transcription that seems to
be active in vivo in CD4+ T cells from persons with spontaneous
control of HIV-1 replication.
RESULTS
Host CDK2 Supports HIV-1 Reverse Transcription in
CD4+ T Cells
Cyclin-dependent kinases have a recognized role for supporting
HIV-1 gene transcription from chromosomal DNA (Mancebo
et al., 1997) but may also facilitate other steps in the HIV-1 life-
cycle. To investigate this, we analyzed the influence of pharma-
cological CDK inhibition on the HIV-1 replication cycle in CD4+
T cells. Primary CD4+ T cells from HIV-1-negative persons718 Cell Host & Microbe 15, 717–728, June 11, 2014 ª2014 Elsevierwere activated ex vivo with CD3/CD8 bispecific antibodies
and IL-2 followed by infection with a GFP-encoding R5-tropic
HIV-1 construct in the presence or absence of Roscovitine or
Olomoucine, two chemical inhibitors of CDKs that can inhibit
HIV-1 mRNA transcription (Wang et al., 2001). These experi-
ments demonstrated that pharmacological inhibition of CDKs
effectively reduced the proportion of GFP-positive CD4+ T cells
and the per-cell levels of early HIV-1 reverse transcripts
(minus-strand strong-stop DNA), intermediate HIV-1 reverse
transcripts (minus-strand DNA), and late, double-stranded HIV-
1 reverse transcription products (Figures 1A–1C); these data
indicate blockade of HIV-1 reverse transcription by pharmaco-
logical CDK inhibitors. Similar observations were made when
cells were infected with a GFP-encoding VSV-G-pseudotyped
HIV-1 virus that causes single-round infections of CD4+ T cells
independently of viral coreceptors (Figures 1D–1F). Altogether,
these findings imply a role of host CDKs, the target molecules
for Roscovitine and Olomoucine, in supporting HIV-1 reverse
transcription. To better define this, we conducted ex vivoInc.
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Cell-Intrinsic Inhibition of HIV-1 RTinfection experiments of CD4+ T cells after small interfering
(siRNA)-mediated knockdown of CDK2 and CDK7, two promi-
nent members of the CDK family that are effectively inhibited
by Roscovitine and Olomoucine and expressed in the cytoplasm
of CD4+ T cells where HIV-1 reverse transcription occurs (Fig-
ure S1A available online). These experiments demonstrated
that siRNA-mediated downregulation of CDK2, but not CDK7,
resulted in a significant reduction of the proportion of HIV-1-pos-
itive cells and of the frequency of per-cell levels of early, interme-
diate, and late HIV-1 reverse transcripts. This was true for cells
infected with R5-tropic (Figures 1G–1I) and with VSV-G-pseudo-
typed (Figures 1J–1L) HIV-1. siRNA directed against CDK1 and
CDK4was effective in downregulating the corresponding protein
expression but had no detectable effect on the proportion of
GFP-positive cells after HIV-1 infection (Figures S1B–S1F).
Silencing of CDK9 reduced cellular susceptibility to productive
HIV-1 infection, consistent with previous findings (Flores et al.,
1999), but had no effect on viral reverse transcription (Figures
S1B–S1E). Altogether, these experiments suggest that CDK2 is
critical for supporting HIV-1 reverse transcription in CD4+ T cells.
HIV-1 RT Is a Substrate for CDK2-Dependent
Phosphorylation
HIV-1 gene products can represent direct targets for phosphor-
ylation by host kinases (Francis et al., 2011). We hypothesized
that CDK2 can support HIV-1 reverse transcription through
phosphorylation of HIV-1 RT. CDKs are requisite proline-
directed serine/threonine kinases with preference for basic
amino acids located C-terminal to the phosphate acceptor
(Nigg, 1993). Therefore, the canonical CDK substrate motif is
Ser/Thr-Pro-X-Arg/Lys, where X can be any amino acid(s). The
HIV-1 RT protein contains seven such CDK motifs (Figure S2A).
Synthetic peptides were generated with sequences derived from
thesemotifs and their surrounding amino acids for an initial rapid
screen of potential CDK phosphorylation sites. Each of these
peptides was assayed as a CDK2 substrate by incubating with
either CDK2/cyclin A or CDK2/cyclin E and ATP (Figure 2A)
followed by mass spectrometric analysis. Robust phosphoryla-
tion of the synthetic peptide containing the motif at Thr216
(corresponding to HIV-1 RT amino acid residues 210–227) was
observed with both CDK2/cyclin A and CDK2/cyclin E, and trace
phosphorylation was observed at two other peptides with CDK2/
cyclin A (Figure 2A). Phosphorylation was not observed with any
other HIV-1 RT peptides harboring CDK phosphorylation motifs
(Figure 2A). When the [210–227] peptide was incubated with
CDK2/cyclin A for 0, 1, and 3 hr, a time-dependent increase in
mass spectral signal at +80 mass units (corresponding to
covalent addition of HPO3) was observed (Figure 2B). When
similar assays were performed with CDK7 or CDK9, the positive
control peptide, but no HIV-1 RT peptides, were phosphorylated
(Figures 2A and S2B), which indicates a selective susceptibility
to phosphorylation by CDK2 and corresponds to our prior obser-
vation that HIV-1 reverse transcription in CD4+ T cells is most
dominantly influenced by CDK2 (Figures 1G–1L).
To further investigate the potential phosphorylation site at
Thr216, the CDK2- phosphorylated [210–227] peptide was sub-
jected to tandemmass spectrometry (MS2). Specific fragmenta-
tion of the phosphorylated peptide showed a strong signal at
98 mass units from the parent peptide peak, correspondingCell Hto the neutral loss of phosphoric acid, a diagnostic characteristic
of serine/therosine-phosphorylated peptide ions (Figure S2C).
Furthermore, with the use of backbone fragmentation, we found
that the y’’11 fragment ion, which runs from Pro217 to Phe227
and does not contain Thr216, is observed at a mass indicating
no phosphate. In contrast, the y’’12 fragment ion, which runs
from Thr216 to Phe227, is observed at a mass indicating the
presence of a phosphate adduct (Figure S4). Because the two
fragments both arise from the singly phosphorylated [210–227]
peptide and are identical in amino acid sequence except for
the Thr216 residue that is selectively contained in the y’’12 frag-
ment ion, these data indicate that Thr216 is indeed the CDK2
phosphorylation site (Figure S2C).
Given that our data suggested that Thr216 represents the only
site in HIV-1 RT susceptible to CDK-dependent phosphorylation,
we performed phosphorylation analyses on the intact HIV-1 RT
protein. Recombinant HIV-1 RT protein was phosphorylated
in vitro and subjected to analysis with western blots. For this pur-
pose, we generated rabbit-derived antibodies that specifically
recognized the HIV-1 RT [210–227] peptide sequence phosphor-
ylated at position Thr216 (Figure S2D). In western blot experi-
ments, two RT bands (p51 and p66 subunits) were detected
with anti-[phospho-210–227] antibodies after incubation with
ATP and CDK2/Cyclin A for 30 min (Figure 2C). An increase in
the intensity of the phospho-RT bands was observed after incu-
bation for 120 min. In order to conclusively determine the phos-
phorylation site in the RT protein, phosphorylated HIV-1 RT
was digested by endoproteinase Lys-C and the digests were
analyzed by mass spectrometry. A mass spectral peak at m/z
2413 was observed in the spectrum arising from the CDK2-
phosphorylated but not the unphosphorylated HIV-1 RT digest.
This peak corresponds to the phosphorylated Lys-C peptide
[202–220], containing the Thr216 CDK phosphorylation site (Fig-
ure 2D, bottom). Phosphorylation at Thr216 was confirmed by
MS2 and MS3 fragmentation (Figure S2E). In contrast, the spec-
trum of the unphosphorylated HIV-RT digest contained a signif-
icant peak at m/z 2,334 corresponding to unphosphorylated
peptide [202–220] (Figure 2D, top); that peak appears substan-
tially weaker in the spectrum from the CDK2-phopsphorylated
RT digest. No other peaks corresponding to phosphorylation at
CDK consensus motifs were observed in either digest (data not
shown). Altogether, these data strongly indicate CDK2-depen-
dent phosphorylation specifically at Thr216 in HIV-1 RT.
We subsequently analyzed the structural position of the tar-
geted Thr216 residue within prior crystal structures of HIV-1 RT
(Ja¨ger et al., 1994; Kohlstaedt et al., 1992). We observed that
Thr216 lies in b strand 11 for both the p51 and p66 subunits, sit-
uated near the interface between the fingers and palm of the
structure (Figure 2E). This solvent-exposed position of Thr216
at the molecular surface is consistent with its role as a target
for cytoplasmic host kinases. In addition, we found that the tar-
geted CDK phosphorylation motif (Thr216 and adjacent Pro217)
was highly conserved across more than 8,000 viral clade A, B, or
C sequences derived from the Los AlamosHIV-1 sequence data-
base (http://www.hiv.lanl.govcontent/index), whereas adjacent
amino acid residues were more variable (Figure 2F). Altogether,
these observations support the notion that the Thr216 residue
in HIV-1 RT is susceptible to CDK phosphorylation and function-
ally and/or structurally important for HIV-1 replication.ost & Microbe 15, 717–728, June 11, 2014 ª2014 Elsevier Inc. 719
Figure 2. HIV-1 RT Is a Substrate for CDK2-Dependent Phosphorylation
(A) Level of phosphorylation observed by semiquantitativeMALDImass spectrometry on synthetic peptides derived fromHIV-1 RT after incubation with indicated
CDKs and ATP for 3 hr. +, phosphopeptide levels < 1%–25%; ++, phosphopeptide levels of 25%–50%; +++,phosphopeptide levels > 50% of total peptide signal
intensity.
(B) Time course for in vitro phosphorylation reaction of synthetic peptide [210–227] incubated with ATP and cyclin A/CDK2 assayed by MALDI-selected ion
monitoring mass spectrometry.
(C) Western blot probed by anti-[phospho-210–227] primary antibody showing time dependence of phosphorylation on recombinant HIV-1 RT protein incubated
with cyclin A/CDK2 and ATP.
(D) MALDI mass spectra of endoproteinase Lys-C proteolyzed unphosphorylated (top) and in vitro cyclin A/CDK2 phosphorylated (bottom) HIV-1 RT protein. The
signal with m/z corresponding to the Thr216 phosphorylated proteolytic peptide is observed in the phosphorylated, but not the unphosphorylated, digest.
(E) Solvent-exposed position of Thr216 in crystal structures of HIV-1 RT.
(F) Entropy of amino acid residues at position 214–219 in indicated clade A, B, and C HIV-1 RT sequences obtained from the Los Alamos HIV-1 sequence
database.
See also Figure S2.
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Cell-Intrinsic Inhibition of HIV-1 RTSubstitution of Thr216 by Alanine Reduces HIV-1
Reverse Transcription
To investigate the functional relevance of CDK2-dependent
phosphorylation of HIV-1 RT, we used site-directedmutagenesis
to construct aGFP-encodingR5-tropic HIV-1 variant inwhich the
targeted Threonine residue at position 216 is replaced by Alanine
(T216A); this leads to removal of a hydroxyl group and abrogates
susceptibility to CDK2-dependent phosphorylation at this posi-
tion. Using western blot experiments with antibodies selectively
recognizing the RT peptide (amino acids 210–227) encompass-
ing phosphorylated Thr216 (Figure S6), we observed a clear
signal corresponding to the detection of phosphorylated RT in720 Cell Host & Microbe 15, 717–728, June 11, 2014 ª2014 ElsevierCD4+ T cells infected with the wild-type (WT) virus; however, no
evidence for phosphorylation of HIV-1 RT was noted after infec-
tion with the variant HIV-1 construct, despite detection of total
HIV-1 RT, although at slightly weaker intensity compared to cells
infected with WT virus (Figure 3A). Similar findings were made
when CD4+ T cells were infected with a VSV-G-WT virus and
the corresponding variant harboring the T216A mutation. Using
coimmunoprecipitation experiments, we also observed that
CDK2 extracted from CD4+ T cells infected with the WT virus,
but not the T216A variant, closely associated with HIV-1 RT (Fig-
ure 3B). These data indicate that phosphorylation of HIV-1 RT at
position Thr216 can occur in CD4+ T cells infected ex vivo.Inc.
Figure 3. HIV-1 RT T216A Mutation Decreases HIV-1 Reverse Transcription
Activated CD4+ T cells were infected ex vivo with GFP-encoding R5-tropic or VSV-G-pseudotyped HIV-1 and with corresponding variants with replacement of
threonine by alanine at position 216 (T216A). Data are expressed as mean ± SD (A) or as box and whisker plots indicating the median, 25% and 75% percentile,
and minimum and maximum of all data (D–G).
(A) Detection of HIV-1 RT with western blots with antibodies directed against total HIV-1 RT (upper row), antibodies directed against the [phospho-210–227] RT
peptide (middle row), or b-actin-specific antibodies (lower row). Left, one experimental example; right, relative signal intensities of indicated bands from n = 6
different experiments.
(B) Whole-protein lysates from CD4+ T cells infected with R5-tropic WT HIV-1 or the T216A variant were precipitated with CDK2 or IgG antibody followed by
interrogation with antibodies directed against HIV-1 RT or against cyclin A or T as controls. One representative experiment out of three is shown.
(C) HIV-1 p24 antigen production in the supernatant of activated CD4+ T cells infected with similar titers of R5-tropic WT HIV-1 or the corresponding T216A
variant. Data were analyzed by fitting a linear model to the log-transformed p24 concentration with maximum likelihood models. Left, one representative
experiment; right, the relative replication capacity of WT and variant viruses calculated on the basis of the slope for the p24 production curves in n = 4
experiments.
(D and F) Proportions of GFP+ CD4+ T cells after infection with GFP-encoding R5-tropic (D) or VSV-G-pseudotyped (F) HIV-1 WT and corresponding T216A
variants.
(E and G) Quantitative analysis of early, intermediate, and late HIV-1 RT transcripts in activated CD4+ cells infected with either WT R5-tropic (E) or VSV-G-
pseudotyped (G) HIV-1 or the corresponding T216A variants.
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Cell-Intrinsic Inhibition of HIV-1 RTWe subsequently assessed the replicative activity of the WT
and variant virus in ex vivo activated CD4+ T cells. A direct com-
parison of the replicative activity of the WT and the variant virus
over an 8-day period demonstrated a significantly reduced
ability of the variant virus to produce HIV-1 p24 antigen; this
is consistent with reduced viral fitness (Figure 3C). We alsoCell Hobserved that infection of CD4+ T cells with the T216A variant
lead to reduced proportions of GFP-positive CD4+ T cells in
comparison to CD4+ T cells infected with the WT virus under
identical conditions (Figure 3D). The lower replicative activity of
the variant virus was associated with reduced levels of early, in-
termediate, and late HIV-1 reverse transcripts, suggesting thatost & Microbe 15, 717–728, June 11, 2014 ª2014 Elsevier Inc. 721
Figure 4. CDK2-Dependent Phosphorylation Enhances Activity and Stability of HIV-1 RT
(A) Assessment of the functional activity of phosphorylated and unphosphorylated HIV-1 RT in a cell-free system. One representative experiment out of four is
shown.
(B) SDS-PAGE gel of limited proteolysis of unphosphorylated (left) and cyclin A/CDK2 phosphorylated (right) HIV-1 RT time course indicated in minutes.
Degradation of the p66 and p51 subunits of HIV-1 RT (major upper and lower bands, respectively) are shown as a function of time and phosphorylation state.
(C) Quantitative comparison of the rates of proteolysis for unphosphorylated and phosphorylated HIV-1 RT asmeasured by SDS-PAGE gel densitometry of Sypro
Ruby-stained HIV-1 RT. (D–G) Box and whisker plots indicating the median, 25% and 75% percentile, and minimum and maximum of all data.
Data are expressed as mean and SEM (A and C). See also Figures S3.
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Cell-Intrinsic Inhibition of HIV-1 RTineffective reverse transcription is the major replicative defect in
this viral variant (Figure 3E). Lower proportions of viral reverse
transcripts were also observed after infection of CD4+ T cells
with a VSV-G-pseudotyped virus harboring the T216A variant,
confirming a lower replicative competence of the T216A variant
and demonstrating that the T216A mutation was associated
with defective HIV-1 reverse transcription independently of
viral entry mechanisms (Figures 3F and 3G). Altogether, these
findings suggest that phosphorylation of HIV-1 RT critically
influences viral fitness through modulation of viral reverse
transcription.
CDK2-Dependent Phosphorylation Increases Function
and Stability of HIV-1 RT
We subsequently determined whether CDK phosphorylation of
HIV-1 RT directly modulates the enzymatic activity of RT. For
this purpose, recombinant HIV-1 RT was exposed to CDK2/
cyclin A, which resulted in 92% and 62% phosphorylation of
the p51 and p66 RT subunits, respectively (Figure S3A–S3C); un-
phosphorylated HIV-1 RT was used as a control. Either HIV-1 RT
was incubated with a poly (A) template, oligo dT primer, and
dTTP followed by monitoring of RT activity via the formation of
RNA-DNA heteroduplexes. These experiments demonstrated
an increased enzymatic activity of phosphorylated HIV-1 RT
(Figure 4A), suggesting that CDK2 phosphorylation supports
the functional activity of the enzyme.
Given that phosphorylation often influences the stability of
proteins (Nishi et al., 2011), we considered whether CDK2 might
serve to modulate the resistance of HIV-1 RT to proteolytic
degradation. Limited proteolysis was employed as an in vitro
tool for probing HIV-1 RT stability. CDK2/cyclin A-phosphory-
lated and -unphosphorylated HIV-1 RT was incubated with sub-
tilisin protease - known to be sensitive to the three-dimensional
conformation of its substrate - at different reaction times ranging
from 2 min to 4 hr (Figures 4B and 4C). These experiments
demonstrated a markedly more rapid decrease in band intensity
for the unphosphorylated HIV-1 RT. Indeed, after 180 min of
exposure to subtilisin, gel densitometry indicated that 45%
of the phosphorylated RT, versus only 20% of the unphosphory-
lated RT, remained undigested, demonstrating that CDK2722 Cell Host & Microbe 15, 717–728, June 11, 2014 ª2014 Elsevierphosphorylation protects HIV-1 RT from protease cleavage.
Moreover, CD4+ T cell infection with the T216A variant in
the presence of proteasome inhibitors (Schwartz et al., 1998)
enhanced viral replication and reverse transcription to levels
observed in cells infected with WT virus, suggesting that protea-
somal degradation of unphosphorylated HIV-1 RT contributes to
replicative defects of the T216A variant (Figure S3D and S3E).
Altogether, these data indicate that CDK2 phosphorylation of
Thr216 protects HIV-1 RT from protease activity and suggest
that its mechanism of actionmay be to stabilize HIV-1 RT against
intracellular proteases, perhaps via conformational modulation.
p21 Suppresses CDK2-Dependent HIV-1 RT
Phosphorylation
The cell-intrinsic CDK inhibitor p21 (waf-1/cip1) is upregulated in
CD4+ T cells from many persons with natural control of HIV-1
replication (elite controllers) (Chen et al., 2011; Sa´ez-Cirio´n
et al., 2011), raising the possibility that p21 has a functional
role for inhibiting CDK2-dependent phosphorylation of RT and
reducing the efficacy of viral reverse transcription in CD4+
T cells from these patients. First, to investigate this, we analyzed
the subcellular localization of p21 in CD4+ T cells from elite
controllers with high-throughput imaging flow cytometry, an
approach that combines standard flow cytometry with high-res-
olution fluorescence microscopy. For this purpose, CD4+ T cells
from elite controllers and HIV-1-negative persons were intracel-
lularly stained with antibodies directed against p21 and the nu-
clear dye DAPI. This analysis demonstrated that p21was located
both in the nuclear and in the cytoplasmic subcellular compart-
ments (Figures 5A and 5B) and did not change substantially after
in vitro activation (Figure S4A). Importantly, we observed that to-
tal, nuclear, and cytoplasmic cell-associated p21was expressed
at significantly higher levels in CD4+ T cells from elite controllers
compared to HIV-1 negative persons, but differences were more
obvious for cytoplasmic p21 than for nuclear p21 (Figures 5A and
5B). This suggests that p21 may be functionally relevant for
inhibiting CDK2-dependent phosphorylation of HIV-1 RT in
the cytoplasm of CD4+ T cells from elite controllers. To further
investigate this, we analyzed HIV-1 reverse transcription in
CD4+ T cells from elite controllers after electroporation withInc.
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Cell-Intrinsic Inhibition of HIV-1 RTp21-specific siRNA, which resulted in effective reduction of p21
protein expression (Figure S4B). We found that, after infection
of CD4+ T cells from elite controllers with either R5-tropic or
VSV-G-pseudotyped HIV-1, siRNA-mediated reduction of p21
expression resulted in enhanced levels of HIV-1-positive cells,
and in increased levels of viral reverse transcripts. Interestingly,
such effects were not visible in CD4+ T cells from HIV-1-negative
persons,most likely because of lower baseline expression of p21
that minimizes biological effects of p21 silencing (Figure 5C–5F).
Moreover, p21 knockdown did not affect HIV-1 replication in
CD4+ T cells from elite controllers infected with the T216A
variant, supporting the notion that p21 inhibition of HIV-1 reverse
transcription depends on phosphorylation of Thr216 (Figure 5C–
5F). In addition, we observed that in CD4+ T cells from elite con-
trollers, the WT virus and the T216A variant showed a similar
replicative activity (Figures 5G and 5H), which represented a
sharp contrast to the replicative advantage of the WT virus in
CD4+ T cells from HIV-1-negative individuals (Figures 3D–3G);
this indicates that the increased viral fitness associated with
RT phosphorylation at position Thr216 is not visible in cells
with high-level p21 expression. Finally, we noted that p21 knock-
down led to increased levels of phosphorylated HIV-1 RT in
CD4+ T cells from elite controllers (ECs) infected with R5-tropic
or VSV-G pseudotyped HIV-1, providing formal evidence for an
inhibitory effect of p21 on CDK2-dependent RT phosphorylation
(Figure 5I). Notably, p21 silencing did not substantially affect
levels of total HIV-1 RT during single-round infection with VSV-
G-pseudotyped virus but appeared to increase levels of total
RT in cells infected with R5-tropic HIV-1 in which the release
of p21-dependent viral inhibition is amplified during multiple
rounds of infection. Altogether, these data suggest that high-
level p21 expression can indirectly inhibit viral reverse transcrip-
tion through blockade of CDK2-dependent phosphorylation of
viral RT.
DISCUSSION
CDKs represent host molecules with a wide range of functions
for regulating cell proliferation, survival, and gene expression,
but also have recognized roles for modulating replication of
viruses in human cells. This seems to be particularly true for hu-
man Herpes viruses (Durand and Roizman, 2008; Zydek et al.,
2010), some of which encode for viral CDK orthologs in order
to avoid dependence on host CDKs for supporting critical viral
replication steps (Kuny et al., 2010). In HIV-1 infection, CDKs
have mostly been recognized for their role in promoting tran-
scriptional elongation of nascent HIV-1 mRNA through phos-
phorylation of host polymerase II (Flores et al., 1999; Mancebo
et al., 1997) and, possibly, direct phosphorylation of HIV-1 Tat
(Ammosova et al., 2006); however, a possible impact of CDKs
on viral preintegration steps remained unknown. Using a combi-
nation of proteomic, biochemical and reverse phosphorylation
approaches, our data provide evidence that the process of
HIV-1 reverse transcription is under tight regulatory control of
CDK2. These data support the emerging recognition of host
kinases as modulators of HIV-1 replication in human CD4+
T cells and suggest that interindividual differences in the CD4+
T cell susceptibility to HIV-1 may, at least to some extent, be
related to a fine-tuned interplay between host kinases and virallyCell Hencoded substrate proteins. In line with this, prior studies
demonstrated that host kinases from the ERK/MAPK family
can enhance chromosomal HIV-1 integration through the induc-
tion of phosphorylation-induced conformational changes in
HIV-1 integrase (Manganaro et al., 2010). Conformational
changes that may result from CDK2-mediated phosphorylation
of RT remain unknown at present but might involve structural
alterations that improve the nucleotide binding capacity of
HIV-1 RT. In this regard, it is interesting that the targeted
Thr216 residue is in immediate proximity to the RT amino acid
residues T215 and K219 with known roles for influencing the
incorporation of nucleotides and pharmaceutical nucleotide
analogues into evolving HIV-1 reverse transcripts (Chamberlain
et al., 2002; Tu et al., 2010). Moreover, recent work has shown
that CDK1, an alternative member of the cyclin-dependent
kinase family, can influence HIV-1 replication through phosphor-
ylation-dependent inactivation of SAMHD1, a host restriction
factor that can otherwise inhibit HIV-1 replication in myeloid
and lymphoid cells (Cribier et al., 2013; White et al., 2013).
Although CDK1 failed to exert marked effects on HIV-1 replica-
tion in ex vivo activated primary CD4+ T cells in our experiments,
these data concur in demonstrating a significant role of CDKs for
modulating HIV-1 replication in human cells.
The role of p21 for cell-intrinsic restriction of HIV-1 has
become increasingly evident over the recent years and is further
supported by findings described in this manuscript. So far, p21
has been implicated in inhibition of HIV-1 replication steps in
macrophages (Allouch et al., 2013; Bergamaschi et al., 2009),
hematopoietic stem cells (Zhang et al., 2007), and CD4+ T cells
(Chen et al., 2011; Elahi et al., 2012), but the proposed underlying
mechanisms and the specific viral replication steps that are tar-
geted seemed to differ in each cell population. In macrophages,
p21 was recently suggested to block HIV-1 reverse transcription
through a blockade of host molecules responsible for maintain-
ing adequate dNTP supply, which in resting cells is critical for
supporting viral replicative activity (Allouch et al., 2013). The
mechanism of p21-mediated HIV-1 restriction in CD4+ T cells
seems to be of particular interest due to the selective upregula-
tion of this protein in elite controllers and its association with
reduced cellular susceptibility of CD4+ T cells to HIV-1 infection
(Chen et al., 2011; Elahi et al., 2012). Our data suggest that p21
can effectively inhibit HIV-1 reverse transcription in CD4+ T cells,
but the underlying mechanism is conceptually different from
pharmacological inhibition of RT and relies on blockade of
CDK2 as a host factor, or ‘‘HIV-1 dependency factor,’’ that is
required for effective viral reverse transcription in CD4+ T cells.
A similar indirect mechanism of viral inhibition appears to occur
at the level of HIV-1 mRNA transcription, where p21 can block
CDK9-mediated phosphorylation of polymerase II and reduce
transcriptional elongation of evolving viral mRNA transcripts
(Chen et al., 2011). As such, p21 seems to be able to restrict at
least two critical HIV-1 replication steps through a combined
blockade of host CDKs supporting HIV-1 replication in CD4+
T cells. This indirect mechanism of viral inhibition appears less
effective than the pharmacodynamic activities of traditional anti-
retroviral agents used for clinical purposes, but avoids a direct
interaction with HIV-1 gene products and in this way may be
less susceptible to viral mutational escape that can very effec-
tively abrogate effects of pharmacological RT inhibitors. In lineost & Microbe 15, 717–728, June 11, 2014 ª2014 Elsevier Inc. 723
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escape variants in ex vivo cultures of HIV-1 infected CD4+
T cells exposed to suboptimal concentrations of pharmacolog-
ical CDK inhibitors (Wang et al., 2001). Notably, by indirectly
blocking CDK-dependent HIV-1 replication steps, p21 seems
to differ from a variety of alternative cell-intrinsic host restriction
factors that target HIV-1 genes or gene products directly and for
which a role in natural immune defense in HIV-1 elite controllers
is less evident. Whether p21 can also inhibit CDK1-dependent
phosphorylation of SAMHD1 (White et al., 2013) and block
HIV-1 replication by reducing CDK1-mediated SAMHD1 inacti-
vation will be an important aspect of future studies.
Elite controllers represent a heterogeneous group of individ-
uals, and underlying immune defense mechanisms against
HIV-1 in these patients seem to vary (Sa´ez-Cirio´n and Pancino,
2013; Walker and Yu, 2013). In many of these patients, highly-
functional HIV-1-specific CD8+ T cell responses appear to repre-
sent the major correlate of immune protection, specifically when
restricted by protective HLA class I alleles (Pereyra et al., 2010).
Yet, a subgroup of elite controllers is able to maintain undetect-
able levels of HIV-1 replication in the absence of strong HIV-
1-specific CD8+ T cells (Emu et al., 2008). Weak HIV-1-specific
CD8+ T cells are also observed in a group of patients who main-
tain undetectable levels of viral replication after being exposed
to a course of antiretroviral therapy in primary HIV-1 infection
(Sa´ez-Cirio´n et al., 2013). A better understanding of synergisms
between cell-intrinsic and CD8 T cell-mediated adaptive
immunity in elite controllers may help to induce a drug-free
remission or functional cure of HIV-1 infection in broader patient
populations.
EXPERIMENTAL PROCEDURES
Patients
Peripheral blood mononuclear cells (PBMCs) from HIV-1-infected individuals
and HIV-1-negative individuals were used for this study according to protocols
approved by the Institutional Review Board of the Massachusetts General
Hospital. All study subjects gave written consent to participate.
HIV-1 Viruses and Constructs
The GFP-encoding R5-tropic and VSV-G-pseudotyped HIV-1 plasmids were
kindly provided by Dr. Dan R. Littman (New York University). Viral particles
were produced by transfecting human embryonic kidney 293T (HEK293T) cells
(NIH AIDS Reagent Program) with the respective HIV-1 plasmids, and, if appli-
cable, pCG-VSV-G, using TransIT-293 (Mirus) in OptiMEM. R5-tropic or VSV-
G-pseudotyped viral variants encoding for a T216A mutation, were generatedFigure 5. Inhibition of p21 (waf-1/cip-1) Increases HIV-1 Reverse Trans
(A) Analysis of the subcellular localization of p21 in CD4+ T cells. PBMCs from El
CD4 (yellow pseudocolor), p21 (green pseudocolor), and DAPI (red pseudocolor) a
plots highlighting differences between an HIV-1 elite controller and an HIV-1-neg
(B) Cumulative average p21 signal intensity in CD4+ T cells from Elite controller
compartments of CD4+ T cells.
(C and D) Proportion of HIV-1-positive CD4+ T cells from EC andHIV-1-negative pe
presence of siRNA-mediated knockdown of p21. The T216A variant virus was us
(E and F) Corresponding analysis of early, intermediate, and late RT transcripts i
(G and H) Comparison of HIV-1 replication patterns of WTHIV-1 and the T216A va
of early, intermediate, and late reverse transcripts (H) are shown.
(I) HIV-1 RT phosphorylation in CD4+ T cells after experimental p21 knockdown. C
infected with R5-tropic or VSV-G pseudotyped HIV-1, and hybridized with antibo
Data are expressed as mean and SEM (I) or as box and whisker plots indicating
(B–H). See also Figure S4.
Cell Hby site-directed mutagenesis by a commercial supplier (Genewiz); the correct
sequence of the variant constructs was confirmed by repeated viral
sequencing. Supernatants containing infectious retroviruses were harvested
48 hr after transfection, centrifuged, and filtered. Viral titers were determined
by measuring p24 levels in the supernatant of infected HEK293T cells, and
confirmed by measuring TCID50 levels in TZM-bl cells (NIH AIDS Reagent
Program).
In Vitro Infection Assays
PBMCs were stimulated in RPMI medium containing 10% fetal calf serum
(FCS), recombinant IL-2 (50 U/ml), and an anti-CD3/CD8 bispecific antibody
(0.5 mg/ml). A homogenous population of activated CD4+ T cells was infected
on day 5 with the indicated HIV-1 viruses for 4h (R5) or 2h (VSV-G) at 37C. Af-
ter two washes, cells were resuspended and plated at 13106 cells per well in a
24-well plate. The CD4+ T cells were subjected to flow cytometric analysis of
GFP+ CD4+ T cells at 96 hr after infection with GFP-encoding R5-tropic HIV-1
or 48 hr after infection with VSV-G-pseudotyped HIV-1 virus. When indicated,
proteasome inhibitors (MG-132, Millipore) were added at a concentration of
1mg/ml. For replication capacity assays, CD4+ T cells were infected with either
WT or T216A-variant R5-tropic HIV-1 viruses. At indicated time intervals,
supernatants were analyzed by p24 ELISA kit (PerkinElmer). Replication ca-
pacities were calculated by fitting a linear model to the log-transformed p24
concentration with maximum likelihood models.
siRNA-Mediated Gene Knockdown
CD4+ T cells were suspended in 100 ml transfection solution (Lonza), and
target-specific or control siRNA (Dharmacon) was added at a concentration
of 4 nmol/ml. Then, samples were transferred into nucleofection cuvettes
and transfected with T-023 in a Nucleofector device (Lonza). Afterwards, cells
were resuspended in medium supplemented with 20% FCS; IL-2 (50 U/ml)
was added 2 hr after transfection. Cells were infected with indicated HIV-1
strains at 24 hr after transfection.
Flow Cytometry
The proportion of CD3+ CD4+ GFP-positive cells was analyzed on an LSRII
flow cytometer (BD Biosciences), and data analysis was performed with
FlowJo software (TreeStar). For imaging flow cytometry experiments, PBMCs
were stained with antibodies directed against CD3 and CD4, fixed, and per-
meabilized. Subsequently, intracellular staining was performed with p21-spe-
cific antibodies (clone F-5, Santa Cruz Biotechnology). The samples were run
on an ImageStream Cytometer (Amnis), and data visualization and colocaliza-
tion analysis were performed with IDEAS Software (Amnis).
Detection of HIV-1 Reverse Transcripts
Cells were harvested 18 hr after infection of activated cells with VSV-G-pseu-
dotyped HIV-1 and 48 hr after infection of activated cells with R5-tropic HIV-1.
RT products were amplified from cell lysates with primers and probes hRU5-
F2, hRU5-R, hRU5-P (early RT transcripts), FST-F1, SS-R4, P-HUS-SS1
(intermediated RT transcripts) and GagF1, GagR1, and P-HUS-103 (late RT
transcripts) (Mbisa et al., 2009). CCR5 was amplified as a housekeepingcription in CD4+ T Cells from Elite Controllers
ite controllers or HIV-1-negative patients were stained with antibodies against
nd subjected to ImageStream analysis. Selected images of single-cell analysis
ative patient are shown.
s (n = 6) and HIV-1 negative persons (n = 6) in total, cytoplasmic and nuclear
rsons after ex vivo infection with R5-tropic or VSV-G-pseudotyped HIV-1 in the
ed where indicated.
n CD4 T cells from elite controllers (n = 5).
riant in CD4+ T cells from EC. Proportions of infected CD4+ T cells (G) and levels
D4+ T cells were transfected with siRNA directed against p21 or control siRNA,
dy against HIV-1 RT, anti-[phospho-210–227] RT, or b-actin.
the median, 25% and 75% percentile, and minimum and maximum of all data
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Serial dilutions of DNA from cell lysates of the HIV-1-infected cell line HEK293T
(provided by Dr. Frederic Bushman, University of Pennsylvania) were used for
reference purposes.
In Vitro Kinase Assays
5 mM HIV-1 RT peptides or RT proteins were incubated with 2 mM ATP
and 550 nM of indicated recombinant CDK (Life Technologies) in NEBuffer
(New England Biolabs). The kinase reaction was stopped by addition of
SDS-PAGE loading buffer. Subsequently, proteins or peptides were analyzed
by western blot or mass spectrometry.
Peptide Analysis
Mass spectrometric analysis of ex vivo kinase assay products was performed
with a Thermo LTQ XL linear ion trap mass spectrometer (Thermo Scientific)
equipped with a vacuum matrix-assisted laser desorption and ionization
(MALDI) source. Synthetic HIV-1 RT peptide samples were mixed with satu-
rated a-Cyano-4-hydroxycinnamic acid (Sigma-Aldrich) in 0.1% trifluoroacetic
acid:acetonitrile (70:30, v/v). A 1.0 ml aliquot of sample and matrix mixture was
dispensed onto the MALDI plate, and the solvent was evaporated at room
temperature.
In Gel Digestion
RT samples were separated by NuPAGE and the protein bands were cut out
and digested by lysyl endopeptidase (Lys-C, Promega) at 37C for 4 hr. The
enzyme Lys-C was added to a final substrate-to-enzyme ratio of 40:1 with
50 mM ammonium bicarbonate (pH 8.5). After digestion, POROS 20 R2 resin
(Applied Biosystems) was added into the digested RT samples for extraction
at 4C for 4 hr. Prior to MALDI mass spectrometric analysis, the digests
were desalted using ZipTip (Millipore) and eluted with CHCAMALDI matrix so-
lution from resins directly onto a MALDI plate and analyzed in single-stage,
MS2 and MS3 modes. Protein bands were identified with Mascot (Matrix Sci-
ence). Identification of phosphopeptide peaks and interpretation of MS2 and
MS3 spectra was performed manually with the assistance of PAWS sequence
analysis software (Genomic Solutions) and ProteinInfo (Rockefeller University;
http://prowl.rockefeller.edu) to calculate theoretical molecular weights.
Western Blots
Protein lysates were prepared from cells with the use of radio-immunoprecip-
itation assay buffer (Sigma-Aldrich) supplemented with the Halt protease
and phosphatase inhibitor cocktail (Pierce). After denaturation, samples
were resolved on Novex 4-12% Tris-Glycine Mini Protein Gels (Life Technolo-
gies), electroblotted to polyvinylidene fluoride membranes (Life Technologies),
and blocked with BSA (Sigma-Aldrich). Blots were hybridized with monoclonal
antibodies against indicated proteins: p21 (clone C-19; Santa Cruz Biotech-
nology), CDK1 (clone 5A6; Thermo Scientific), CDK4 (clone PA5-14445;
Thermo Scientific), CDK9 (clone PA5-19674; Thermo Scientific), CDK2 (clone
78B2; Cell Signaling), CDK7 (cloneMO1; Cell Signaling Technology), Lamin B1
(clone D4Q4Z; Cell Signaling), and b-actin (AB8224; Abcam). For detection of
phosphorylated HIV-1 RT, blots were hybridized with antibodies against phos-
phorylated HIV-1 RT generated by vaccination of rabbits with the phosphory-
lated target peptide (LRWGFTpTPDKKHQKEPPF) according to standard
procedures by a commercial manufacturer (ThermoFisher Scientific). Detec-
tion of total HIV-1 RT was performed with a commercially available antibody
(AB63911; Abcam). After washing, membranes were probed with Cy5-labeled
secondary antibody (ECL Plex; GE Healthcare) for 1 hr for chemifluorescence
detection by Typhoon 9410 (AmershamBiosciences) with excitation and emis-
sion wavelengths of 649 and 670. Alternatively, signals were visualized with
secondary goat anti-rabbit antibodies labeled with IRDye 800CW followed
by quantification of signals with Odyssey Image System (Li-Cor) and Image
J software (National Institutes of Health).
Coimmunoprecipitation Assays
Protein lysates from CD4+ T cells were incubated in spin columns coated with
anti-CDK2 (clone 78B2; Cell Signaling) for 12 hr at 4C. After washing, protein
complexes were eluted, boiled, and subjected to SDS-PAGE followed by
western blotting with antibodies against HIV-1 RT (AB63911; Abcam), cyclin
A (clone BF683; Cell Signaling), and cyclin T (clone 8744; Cell Signaling).726 Cell Host & Microbe 15, 717–728, June 11, 2014 ª2014 ElsevierDetermination of HIV-1 RT Stability
Recombinant HIV-1 RT was phosphorylated by a CDK kinase assay followed
by limited proteolysis with subtilisin (Sigma-Aldrich). The 0.16 mg/ml RT sam-
ples were incubated with subtilisin protease (1 mg/ml) in 100 mM Tris (pH 8.5)
buffer at 30C for 2, 30, 60, 120, 180, or 240min (Serrano et al., 1984). For anal-
ysis, the collected samples were heated with SDS sample buffer at 90C, alky-
lated with iodoacetamide, and separated by SDS gel electrophoresis. Then,
the gels were fixed in 40% methanol and 10% glacial acetic acid for 1 hr
and stained with SYPRO Ruby Protein Gel Stain (Life Technologies) under
dark conditions overnight. After being washed twice in 10% methanol and
7% glacial acetic acid for 1 hr, the stained gels were scanned on a Typhoon
9410 Imager with a green 532 nm excitation laser and 610BP30 emission filter.
Densitometry quantitation was performed with ImageQuant software (Molec-
ular Dynamics).
Functional Assessment of HIV-1 RT
After in vitro kinase assays, 0.25 U of RT and phospho-RT were analyzed with
the EnzCheck RT assay (Life Technologies). The HIV-1 RTs were incubated
with 0.125 mg/ml Oligo d(T)16 primer, 2.5 mg/ml poly(A) ribonucleotide template,
and 5 mM dTTP at room temperature for 10, 20, and 30 minutes. The reaction
was quenched by adding EDTA, and the RT activity was measured with a fluo-
rometric assay.
Statistical Analysis
Data are expressed as mean and SD or SEM or as box and whisker plots indi-
cating the median, the 25% and 75% percentile and the minimum and
maximum of all data. Differences between different cohorts or different exper-
imental conditions were tested for statistical significance with paired or un-
paired Student’s t tests as appropriate. A p value of 0.05 was considered
significant.
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